



July 10, 2026

BSE Limited
P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018

Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, kindly find enclosed herewith a copy of the certificate received from KFin Technologies Limited, the Registrar and Share Transfer Agent of the Company for the quarter ended on June 30, 2026.

Request you to kindly take the above on record.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Hitesh Kumar Jain
Company Secretary &
Compliance Officer

Encl.: A/a

R:/KFIN/R74(5)

Date: 09.07.2026

THE COMPANY SECRETARY
MANKIND PHARMA LIMITED
236, OKHLA INDUSTRIAL ESTATE
PHASE – 3, NEW DELHI, 110020

Dear Sir(s),

Sub: Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories & Participants) Regulations 2018 ('Regulations') for the quarter ended June 30, 2026.

With reference to the above captioned Regulations, we hereby confirm that during the period from April 01, 2026, to June 30, 2026, we have not received any requests for dematerialisation/rematerialisation of shares of Mankind Pharma Limited, as required under Regulation 74(5) of SEBI (Depositories and participants) Regulations 2018.

Thanking you,

Yours faithfully,
KFIN TECHNOLOGIES LIMITED



Dnyanesh Gharote
Vice President

Operations Centre:

KFin Technologies Limited, Selenium, Tower B, Plot No-31 & 32,
Financial District, Nanakramguda, Serilingampally,
Hyderabad – 500032, Telangana, India.

KFin Technologies Limited 

Registered Office:

KFin Technologies Limited, 301, The Centrium,
3rd Floor, 57, Lal Bahadur Shastri Road, Nav Pada,
Kurla (West), Mumbai - 400 070, Maharashtra

CIN: L72400MH2017PLC444072